RecruitingPhase 1Phase 2NCT06459063

Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint

A Placebo-controlled Study of Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint


Sponsor

Kaplan Medical Center

Enrollment

46 participants

Start Date

Jun 10, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a single center trial to assess the safety and efficacy of intra-articular administration of Allocetra to patients with 1st CMC thumb joint osteoarthritis (OA).


Eligibility

Min Age: 40 Years

Inclusion Criteria6

  • Subjects eligible for this clinical study must fulfill all of the following:
  • Age 40 years or older.
  • Patients with OA of the first CMC joint of the target thumb (basal thumb joint) who have failed conventional therapies, with pain assessed when not taking analgesic medications.
  • Score of 6 or higher on the Functional Index for Hand Osteoarthritis (FIHOA).
  • X-ray confirming OA of the first CMC joint of the target thumb with a Grade of 2 or 3 according to Eaton classification.
  • Blood tests from up to three months before treatment within protocol-defined limits.

Exclusion Criteria9

  • Subjects not eligible for this study include those that have any of the following:
  • Any significant injury, fracture, surgery, active local infection, deformity, severe Carpal Tunnel Syndrome (CTS), DeQuervain's tenosynovitis, trigger finger, or a ganglion cyst of the target hand.
  • History of chondrocalcinosis in the target joint, concomitant rheumatic disease.
  • Previous intra-articular injection of steroid, hyaluronate, or other agent, into the target joint within 3 months prior to screening visit.
  • Other limb pain of unknown etiology, or clinically significant widespread pain syndrome, e.g., fibromyalgia.
  • Pain in the limb clinically assessed to arise from an origin which is not the affected thumb joint (wrist pain, shoulder pain, etc.).
  • Secondary OA such as gout, hemochromatosis, rheumatoid/psoriatic arthritis.
  • Bleeding disorders, cognitive disorder, neurologic disease or other major medical condition which may interfere with study participation, treatment, assessments, or results.
  • For women of childbearing potential, a positive pregnancy test.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAllocetra - Safety run-in phase

Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.

OTHERPlacebo

Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.

DRUGAllocetra - Randomization phase

Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.


Locations(1)

Kaplan Medical Center

Rehovot, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06459063


Related Trials